Madrigal Drug Patent Portfolio
Madrigal owns 1 orange book drug protected by 5 US patents Given below is the list of Madrigal's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376517 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | 17 Sep, 2033 | Active |
| US11564926 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | 17 Sep, 2033 | Active |
| US11986481 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | 17 Sep, 2033 | Active |
| US9266861 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | 17 Sep, 2033 | Active |
| US7452882 | Thyroid hormone analogs | 12 Sep, 2026 | Active |
Latest Legal Activities on Madrigal's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Madrigal.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Jun, 2024 | US7452882 |
|
Email Notification
Critical
| 26 Jun, 2024 | US7452882 |
| Initial letter Re: PTE Application to regulating agency | 07 May, 2024 | US9266861 |
| Initial letter Re: PTE Application to regulating agency | 07 May, 2024 | US7452882 |
| Requirement for information sent under 37 CFR 1.750 | 07 May, 2024 | US7452882 |
| Patent Term Extension Application under 35 USC 156 Filed | 02 May, 2024 | US7452882 |
| Patent Term Extension Application under 35 USC 156 Filed | 02 May, 2024 | US9266861 |
|
Email Notification
Critical
| 17 Apr, 2024 | US7452882 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 17 Apr, 2024 | US7452882 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 11 Apr, 2024 | US9266861 |
|
Email Notification
Critical
| 11 Apr, 2024 | US9266861 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 29 Aug, 2023 | US9266861 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Aug, 2023 | US9266861 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Feb, 2023 | US10376517 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 31 Jan, 2023 | US11564926 |
Madrigal's Family Patents
Madrigal Drug List
Given below is the complete list of Madrigal's drugs and the patents protecting them.
1. Rezdiffra
Rezdiffra is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10376517 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
17 Sep, 2033
(8 years from now)
| Active |
| US11564926 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
17 Sep, 2033
(8 years from now)
| Active |
| US11986481 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
17 Sep, 2033
(8 years from now)
| Active |
| US9266861 | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
17 Sep, 2033
(8 years from now)
| Active |
| US7452882 | Thyroid hormone analogs |
12 Sep, 2026
(1 year, 10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rezdiffra's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List